Goldman Sachs
SPRY icon

Goldman Sachs’s ARS Pharmaceuticals SPRY Stock Holding History

Goldman Sachs’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.05M Sell
380,770
-343,449
-47% -$2.95M ﹤0.01% 4334
2026
Q1 		$5.82M Sell
724,219
-87,817
-11% -$842K ﹤0.01% 3552
2025
Q4 		$9.46M Sell
812,036
-513,703
-39% -$5M ﹤0.01% 3146
2025
Q3 		$13.3M Sell
1,325,739
-138,573
-9% -$1.99M ﹤0.01% 2677
2025
Q2 		$25.6M Buy
1,464,312
+746,359
+104% +$10.8M ﹤0.01% 1910
2025
Q1 		$9.03M Sell
717,953
-168,164
-19% -$2.02M ﹤0.01% 2786
2024
Q4 		$9.35M Buy
886,117
+610,262
+221% +$8.55M ﹤0.01% 2864
2024
Q3 		$4M Sell
275,855
-164,884
-37% -$1.96M ﹤0.01% 3546
2024
Q2 		$3.75M Sell
440,739
-21,977
-5% -$195K ﹤0.01% 3421
2024
Q1 		$4.73M Buy
462,716
+321,615
+228% +$2.4M ﹤0.01% 3137
2023
Q4 		$773K Sell
141,101
-98,347
-41% -$431K ﹤0.01% 4528
2023
Q3 		$905K Buy
239,448
+116,295
+94% +$763K ﹤0.01% 4336
2023
Q2 		$825K Sell
123,153
-73,351
-37% -$490K ﹤0.01% 4473
2023
Q1 		$1.28M Buy
196,504
+83,609
+74% +$642K ﹤0.01% 4206
2022
Q4 		$963K Buy
112,895
+13,243
+13% +$85.9K ﹤0.01% 4449
2022
Q3 		$526K Sell
99,652
-23,634
-19% -$116K ﹤0.01% 4937
2022
Q2 		$523K Buy
123,286
+21,595
+21% +$75.3K ﹤0.01% 5052
2022
Q1 		$357K Buy
101,691
+23,458
+30% +$102K ﹤0.01% 5555
2021
Q4 		$521K Buy
78,233
+23,884
+44% +$194K ﹤0.01% 5353
2021
Q3 		$543K Buy
+54,349
New +$1.34M ﹤0.01% 5144
2021
Q1 		– Sell
-87,813
Closed -$4.07M – 6329
2020
Q4 		$4.07M Buy
+87,813
New +$2.93M ﹤0.01% 3161

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tyro Capital Management Miami, Florida $446M AUM 84.15% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Goldman Sachs's SPRY Position: Q2 2026 in Review

Goldman Sachs reduced its ARS Pharmaceuticals (SPRY) stake by 47% in Q2 2026, selling an estimated $2.95M and leaving 380,770 shares worth $3.05M. The position accounts for ﹤0.01% of the portfolio, ranked #4334.

Goldman Sachs first reported a position in SPRY in Q4 2020 and has held it in 21 quarters since. The position peaked at $25.6M in Q2 2025. 208 funds tracked by Wall St. Rank hold SPRY as of Q2 2026.

  • Goldman Sachs held 380,770 shares of ARS Pharmaceuticals worth $3.05M as of Q2 2026.
  • Goldman Sachs sold 343,449 ARS Pharmaceuticals shares in Q2 2026, an estimated $2.95M.
  • ARS Pharmaceuticals made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #4334 holding.
  • Goldman Sachs first reported a position in ARS Pharmaceuticals in Q4 2020 and has held it in 21 quarters since.
  • Goldman Sachs's ARS Pharmaceuticals position peaked at $25.6M in Q2 2025.
  • 208 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.